Materialise (MTLS) Earnings Date & Reports

Key Takeaways

• Total revenue rose 2.1% year over year to €67.7 million, or 4.9% excluding the impact of recent divestitures in the Manufacturing segment.
• Net profit was €1.4 million, or €0.02 per diluted share, down from €1.8 million (€0.03 per share) in the prior-year quarter.
• Adjusted EBIT (earnings before interest and taxes) declined to €2.5 million, with an adjusted EBIT margin of 3.7% versus 4.4% a year earlier.
• The Medical segment led growth with revenue up 9.7%, while Software revenue declined roughly 4% amid cautious industrial spending.
• Management reaffirmed full-year 2026 guidance for revenue of €273–283 million and adjusted EBIT of €12–14 million.
• The net cash position climbed to €82.5 million, up nearly €12 million from the start of the year, supported by strong operating cash flow.
• For more on Materialise, explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• Discover actionable ideas across the market with Trending AI Robots.

Earnings Context and Why It Matters

Materialise's third-quarter report offers a timely read on how a diversified 3D printing company is navigating divergent demand across its three segments. The Belgian firm's Medical business has been its growth engine, while its Software unit faces an uncertain industrial spending environment, and its Manufacturing segment is still absorbing recent divestitures. For investors, the quarter tests whether the company can convert steady top-line momentum into durable profitability, particularly as it steps up research and development (R&D) investment. The reaffirmed full-year guidance also matters because it signals management's confidence in its repositioning toward high-value series production and medical solutions.

Reported Results

For the third quarter ended September 30, 2026, Materialise reported total revenue of €67.7 million, up 2.1% from €66.3 million a year earlier. Excluding last year's revenue from recently divested businesses in the Manufacturing segment, revenue rose 4.9% year over year.

Net profit was €1.4 million, or €0.02 per diluted share, compared with €1.8 million, or €0.03 per diluted share, in the prior-year period. Adjusted EBIT came in at €2.5 million, down from €2.9 million, with an adjusted EBIT margin of 3.7% versus 4.4% a year earlier. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) was €8.0 million, down from €8.4 million.

By segment, Medical revenue increased 9.7% to €36.5 million, while Software revenue fell to €9.9 million from €10.3 million. Manufacturing revenue was €21.3 million, down from €22.7 million, though it rose 1.5% excluding divestitures. Gross profit climbed 3.7% to €39.0 million, lifting the gross margin to 57.7%.

AI Screener

For traders and investors looking to move beyond single-stock analysis, Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps users filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. The platform lets users scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. By surfacing trade ideas, trending names, breakout candidates, and market opportunities more efficiently than manual screening, it can complement earnings-driven research. Consider exploring the AI Screener to identify opportunities that align with your own criteria.

Market Reaction and Investor Sentiment

Materialise's Q3 results landed as a mixed report. Revenue and earnings per share came in below consensus expectations, with GAAP (Generally Accepted Accounting Principles) EPS of €0.02 against estimates around €0.04 and revenue modestly below forecasts. The stock has shown notable momentum over the past year, and the quarter's softer adjusted profitability, driven by higher R&D spending and one-time costs, likely kept near-term sentiment cautious. At the same time, the reaffirmed full-year guidance and a strengthening net cash position provided a stabilizing counterweight, reinforcing the view that management remains disciplined on costs and cash generation even as it invests for future growth.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will focus on whether Materialise can sustain Medical's near double-digit growth while stabilizing its Software and Manufacturing segments. Management reaffirmed full-year revenue guidance of €273–283 million and adjusted EBIT of €12–14 million, implying a heavier lift in the fourth quarter to reach the midpoint.

Key factors to watch include the pace of R&D investment in the Medical segment, which is intended to capture future opportunities but is compressing near-term margins. The Manufacturing segment's shift toward high-value series production—driven by aerospace, semiconductor, and defense demand—will also be important, as series production revenue grew more than 30% year over year in the quarter.

Additionally, Software revenue remains sensitive to extended sales cycles and cautious customer spending, so any stabilization in industrial demand would be a meaningful signal. Finally, the company's growing net cash position and ongoing share buyback program provide balance-sheet flexibility that could support both reinvestment and shareholder returns in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations